Omnicell (OMCL)
(Delayed Data from NSDQ)
$43.42 USD
+0.64 (1.50%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $43.37 -0.05 (-0.12%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Omnicell, Inc. [OMCL]
Reports for Purchase
Showing records 101 - 120 ( 337 total )
Company: Omnicell, Inc.
Industry: Medical Info Systems
Read Throughs from PINC Guide Down: Weaker Hospital Volumes
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Provider: Zacks Investment Research
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Healthcare IT: Recap from Large HC Industry Conference
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Provider: Zacks Investment Research
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Bull vs. Bear Case; See 110% Upside and 13% Downside from Current Levels
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Reducing Workforce by ~9%; Expect ~7.5% Positive Impact to Annual Adj. Profits
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
Company: Omnicell, Inc.
Industry: Medical Info Systems
3Q Miss; FY Guidance Lowered by 8% on Revenues and 28% on Adj. EBITDA
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department